.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,921,393

« Back to Dashboard

Claims for Patent: 8,921,393

Title:Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Abstract: Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
Inventor(s): Weiner; David M. (San Diego, CA), Davis; Robert E. (San Diego, CA), Brann; Mark R. (Rye, NH), Andersson; Carl-Magnus A. (Hjarup, SE), Uldam; Allan K. (Vaerloese, DK)
Assignee: ACADIA Pharmaceuticals Inc. (San Diego, CA)
Application Number:14/086,838
Patent Claims: 1. A method for treating a neurodegenerative disease, or a symptom thereof, comprising administering to a patient suffering from a neurodegenerative disease, or a symptom thereof, a therapeutically effective amount of a compound of formula (I): ##STR00010## or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the salt is a tartrate salt.

3. The method of claim 1, wherein the salt is a hydrochloride salt.

4. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is from about 0.001 mg to about 50 mg.

5. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 10 mg.

6. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 10 mg.

7. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 25 mg.

8. The method of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 50 mg.

9. The method of claim 1, wherein the compound of formula (I) is administered daily.

10. The method of claim 1, wherein the compound of formula (I) is administered once daily.

11. The method of claim 1, wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, Spinocerebellar Atrophy, Tourette's Syndrome, Friedrich's Ataxia, Machado-Joseph's disease, Lewy Body Dementia, Dystonia, Progressive Supranuclear Palsy, and Frontotemporal Dementia.

12. The method of claim 1, wherein the neurodegenerative disease is Parkinson's disease.

13. The method of claim 1, wherein the neurodegenerative disease is Alzheimer's disease.

14. The method of claim 12, wherein a tartrate salt of the compound of formula (I) is administered.

15. The method of claim 13, wherein a tartrate salt of the compound of formula (I) is administered.

16. The method of claim 1, wherein the symptom is psychosis secondary to the neurodegenerative disease.

17. The method of claim 14, wherein the symptom is psychosis secondary to the neurodegenerative disease.

18. The method of claim 15, wherein the symptom is psychosis secondary to the neurodegenerative disease.

19. A method for treating psychosis secondary to a neurodegenerative disorder, comprising administering to a patient suffering from a neurodegenerative disorder, a therapeutically effective amount of a compound of formula (I): ##STR00011## or a pharmaceutically acceptable salt thereof.

20. The method of claim 19, wherein the salt is a tartrate salt.

21. The method of claim 19, wherein the salt is a hydrochloride salt.

22. The method of claim 19, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is from about 0.001 mg to about 50 mg.

23. The method of claim 19, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 10 mg.

24. The method of claim 19, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 10 mg.

25. The method of claim 19, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 25 mg.

26. The method of claim 19, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is about 50 mg.

27. The method of claim 19, wherein the compound of formula (I) is administered daily.

28. The method of claim 19, wherein the compound of formula (I) is administered once daily.

29. The method of claim 19, wherein the compound of formula (I) is administered in combination with an additional therapeutic agent.

30. The method of claim 29, wherein the additional therapeutic agent is selected from the group consisting of levodopa, bromocriptine, pergolide, ephedrine sulfate, pemoline, mazindol, d,1-.alpha.-methylphenethylamine, methylphenidate, pramipexole, modafinil, and ropinirole.

31. The method of claim 29, wherein the additional therapeutic agent is an anti-dyskinesia agent.

32. The method of claim 29, wherein the additional therapeutic agent is an anti-dyskinesia agent selected from the group consisting of baclofen, botulinum toxin, clonazepam, and diazepam.

33. The method of claim 29, wherein the additional therapeutic agent is an anti-dystonia, anti-myoclonus, or anti-tremor agent selected from the group consisting of baclofen, botulinum toxin, clonazepam, and diazepam.

34. The method of claim 29, wherein the additional therapeutic agent is an anti-psychotic agent with dopaminergic receptor antagonism.

35. The method of claim 29, wherein the additional therapeutic agent is an anti-psychotic agent selected from the group consisting of chlorpromazine, haloperidol, molindone, thiordazine, a phenothiazine, a butyrophenone, diphenylbutylpiperidine, thioxanthines, substituted benzamides, sertindole, amisulpride, ziprasidone, aripiprazole, clozapine, olanzapine, risperidone, N-desmethylclozapine, N-desmethylolanzapine, and 9-OH-risperidone.

36. The method of claim 29, wherein the diphenylbutylpiperidine is pimozide, the thioxanthine is fluphenthixol, and the substituted benzamide is sulpiride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc